Trametinib response in heavily pretreated high-grade ovarian cancer: one step towards precision medicine

This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research